Skip to main content
Log in

Cisplatin plus gemcitabine cost effective for metastatic BC in China

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Notes

  1. 2019 US dollars

  2. gross domestic product

Reference

  • Rui M, et al. Economic Evaluation of Cisplatin Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine for the Treatment of First-Line Advanced Metastatic Triple-Negative Breast Cancer in China: Using Markov Model and Partitioned Survival Model. Advances in Therapy : 9 Jul 2020. Available from: URL: http://doi.org/10.1007/s12325-020-01418-7

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cisplatin plus gemcitabine cost effective for metastatic BC in China. PharmacoEcon Outcomes News 858, 5 (2020). https://doi.org/10.1007/s40274-020-6978-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-020-6978-z

Navigation